AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10469292 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1609
Study 8834129 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5 to 10 mg/day)
Number of subjects: 152
Study 2390281 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium sulphate (group A - 27 patients)
Number of subjects: 54
Study 2390281 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group B - 27 patients)
Number of subjects: 54
Study 7361799 — intervention group
Group type: EXPERIMENTAL
Intervention: 5th-grade level warfarin drug monograph
Number of subjects: 108
Study 7361799 — intervention group
Group type: COMPARATOR
Intervention: 10th-grade level warfarin drug monograph
Number of subjects: 108
Study 31677152 — intervention group
Group type: EXPERIMENTAL
Intervention: Attachment and Biobehavioral Catch‐Up (ABC) intervention
Number of subjects: 100
Study 31677152 — intervention group
Group type: COMPARATOR
Intervention: Control intervention
Number of subjects: 100
Study 30737199 — intervention group
Group type: EXPERIMENTAL
Intervention: rehabilitation+early ACL reconstruction (ACLR) (n=59)
Number of subjects: 121
Study 30737199 — intervention group
Group type: COMPARATOR
Intervention: rehabilitation+optional delayed ACLR (n=58)
Number of subjects: 121
Study 30737199 — intervention group
Group type: COMPARATOR
Intervention: rehabilitation alone (n=29)
Number of subjects: 121
Study 26859463 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance training program (12 weeks)
Number of subjects: 91
Study 27255133 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic single site (LESS) cholecystectomy
Number of subjects: 0
Study 27255133 — intervention group
Group type: COMPARATOR
Intervention: Classic laparoscopic cholecystectomy
Number of subjects: 0
Study 25174568 — intervention group
Group type: COMPARATOR
Intervention: Standard NHS Health Check invitation letter, information sheet, and reminder letter at 12 weeks for nonattenders (Group A)
Number of subjects: 0
Study 25174568 — intervention group
Group type: EXPERIMENTAL
Intervention: QBE questionnaire 1 week before standard invitation, information sheet, and reminder letter (Group B)
Number of subjects: 0
Study 25174568 — intervention group
Group type: EXPERIMENTAL
Intervention: QBE questionnaire plus £5 retail voucher (Group C)
Number of subjects: 0
Study 22291928 — intervention group
Group type: EXPERIMENTAL
Intervention: Sound intensity modification
Number of subjects: 0
Study 22291928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatching emotional prosodies
Number of subjects: 0
Study 22291928 — intervention group
Group type: EXPERIMENTAL
Intervention: Mismatching emotional prosodies with reduced sound intensity
Number of subjects: 0
Study 21060031 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (37.5 mg daily for 7 days followed by 75 mg daily for 21 days)
Number of subjects: 66
Study 21060031 — intervention group
Group type: COMPARATOR
Intervention: Gabapentin (300 mg once per day for 3 days, then 300 mg twice per day for 3 days, then 300 mg three times per day for 22 days)
Number of subjects: 66
Study 18058343 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion hydrochloride (10 weeks)
Number of subjects: 722
Study 18058343 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 722
Study 15859023 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% NaCl infusion
Number of subjects: 14
Study 12223249 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-month family intervention
Number of subjects: 0
Study 9788455 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (200000 IU for mothers, 25000 IU for infants)
Number of subjects: 9424
Study 9788455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9424
Study 7626570 — intervention group
Group type: EXPERIMENTAL
Intervention: One drop regimen of dapiprazole
Number of subjects: 0
Study 7626570 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 + 1 drop regimen of dapiprazole
Number of subjects: 0
Study 7626570 — intervention group
Group type: COMPARATOR
Intervention: 2 + 2 drop regimen of dapiprazole (reference)
Number of subjects: 0
Study 7626570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2791122 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma-neutron irradiation using 252Cf, physical dose 2 Gy
Number of subjects: 20
Study 2791122 — intervention group
Group type: COMPARATOR
Intervention: Conventional sources of radiation gamma 226Ra
Number of subjects: 20
Study 31225839 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention consisting of four one‐on‐one sessions with a nurse interventionist during the patient's first, second, fourth, and sixth week of radiation treatment
Number of subjects: 18
Study 31225839 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 18
Study 28974568 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP-VVV 4th quartile (≥17.34 mm Hg)
Number of subjects: 3843
Study 28974568 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP-VVV 3rd quartile (13.86-17.33 mm Hg)
Number of subjects: 3843
Study 28974568 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP-SD as a continuous variable
Number of subjects: 3843
Study 28974568 — intervention group
Group type: EXPERIMENTAL
Intervention: SBP-VVV quartiles (1st to 4th)
Number of subjects: 3843
Study 26269446 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered knee-ankle-foot orthosis
Number of subjects: 7
Study 26269446 — intervention group
Group type: COMPARATOR
Intervention: Drop-locked knee-ankle-foot orthosis
Number of subjects: 7
Study 23880908 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 4 mg (n=22)
Number of subjects: 46
Study 23880908 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=20)
Number of subjects: 46
Study 22910758 — intervention group
Group type: COMPARATOR
Intervention: Statin therapy
Number of subjects: 153962
Study 22910758 — intervention group
Group type: COMPARATOR
Intervention: Intensive dose statin therapy
Number of subjects: 153962
Study 22910758 — intervention group
Group type: COMPARATOR
Intervention: Fibrate therapy
Number of subjects: 153962
Study 19261367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (verapamil and diltiazem)
Number of subjects: 206
Study 19261367 — intervention group
Group type: COMPARATOR
Intervention: Adenosine
Number of subjects: 206
Study 19261367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (verapamil)
Number of subjects: 206
Study 19261367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers (diltiazem)
Number of subjects: 206
Study 19261367 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 206
Study 17191143 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated mailing condition (received the summary booklet plus 7 additional booklets)
Number of subjects: 169
Study 17191143 — intervention group
Group type: COMPARATOR
Intervention: Single mailing condition (received one booklet summarizing all of the relapse prevention information)
Number of subjects: 169
Study 15183850 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% solution (v/v) of essential oil of Australian lemon myrtle (Backhousia citriodora)
Number of subjects: 31
Study 15183850 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (olive oil)
Number of subjects: 31
Study 11773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PCT) consisting of two cycles of mitomycin (6 mg/m(2), day 1), ifosfamide (1.5 g/m(2), days 1 to 3), and cisplatin (30 mg/m(2), days 1 to 3), plus two additional postoperative cycles for responding patients.
Number of subjects: 355
Study 11773176 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy (PCT)
Number of subjects: 355
Study 11773176 — intervention group
Group type: COMPARATOR
Intervention: Primary surgery (PRS)
Number of subjects: 355
Study 9538626 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride 25mg t.i.d. for 3 weeks
Number of subjects: 42
Study 9538626 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 9538626 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosulpiride
Number of subjects: 42
Study 8076723 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinician-initiated telephone intervention at 6, 9, and 12 weeks postfitting.
Number of subjects: 60
Study 8076723 — intervention group
Group type: COMPARATOR
Intervention: Control group encouraged to contact the center only at the time of dispensing.
Number of subjects: 60
Study 2511687 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate (mean dose 12.9 mg; range 7.7‐14.9)
Number of subjects: 36
Study 2511687 — intervention group
Group type: EXPERIMENTAL
Intervention: Buccal nitroglycerine (5 mg)
Number of subjects: 36
Study 2511687 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (nitro TTS 10)
Number of subjects: 36
Study 1066200 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied every 6 months
Number of subjects: 464
Study 1066200 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconium silicate paste containing 9% stannous fluoride (Zircate Treatment Paste) applied once each year
Number of subjects: 464
Study 1066200 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoride zirconium silicate paste (tzircate Prophylaxis Paste) applied once each year
Number of subjects: 464
Study 31248461 — intervention group
Group type: EXPERIMENTAL
Intervention: 12MP + Tet + TLR agonist without IFA (V0)
Number of subjects: 51
Study 31248461 — intervention group
Group type: EXPERIMENTAL
Intervention: 12MP + Tet + TLR agonist with IFA (V1)
Number of subjects: 51
Study 31248461 — intervention group
Group type: EXPERIMENTAL
Intervention: 12MP + Tet + TLR agonist with IFA (V6)
Number of subjects: 51
Study 31248461 — intervention group
Group type: EXPERIMENTAL
Intervention: LPS (cohort 1)
Number of subjects: 51
Study 31248461 — intervention group
Group type: EXPERIMENTAL
Intervention: polyICLC (cohort 2)
Number of subjects: 51
Study 31248461 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-related dose-limiting toxicities (DLTs)
Number of subjects: 51
Study 28403406 — intervention group
Group type: EXPERIMENTAL
Intervention: C-E clamp technique
Number of subjects: 81
Study 28403406 — intervention group
Group type: EXPERIMENTAL
Intervention: V-E clamp technique
Number of subjects: 81
Study 24977698 — intervention group
Group type: EXPERIMENTAL
Intervention: P30 (30 s rest)
Number of subjects: 19
Study 24977698 — intervention group
Group type: EXPERIMENTAL
Intervention: P60 (60 s rest)
Number of subjects: 19
Study 24977698 — intervention group
Group type: EXPERIMENTAL
Intervention: P120 (120 s rest)
Number of subjects: 19
Study 23823377 — intervention group
Group type: EXPERIMENTAL
Intervention: CO‐ED system (computer‐assisted instruction about major hypertension topics)
Number of subjects: 60
Study 23823377 — intervention group
Group type: COMPARATOR
Intervention: Internet search (search engine for information about hypertension)
Number of subjects: 60
Study 21730307 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/d for 3 days before surgery
Number of subjects: 42
Study 21730307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 21730307 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 42
Study 18538111 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 75 mg
Number of subjects: 32
Study 18538111 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 32
Study 18538111 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 32
Study 18538111 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren 600 mg
Number of subjects: 32
Study 15946638 — intervention group
Group type: EXPERIMENTAL
Intervention: Handsfree phone mode
Number of subjects: 48
Study 15946638 — intervention group
Group type: EXPERIMENTAL
Intervention: Handheld phone mode
Number of subjects: 48
Study 15946638 — intervention group
Group type: COMPARATOR
Intervention: Dialling (both phone modes)
Number of subjects: 48
Study 15946638 — intervention group
Group type: COMPARATOR
Intervention: Conversation (both phone modes)
Number of subjects: 48
Study 15946638 — intervention group
Group type: COMPARATOR
Intervention: Dialling and conversation (both phone modes)
Number of subjects: 48
Study 12117049 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-96 (2.5 g orally 3 times daily for 4 weeks)
Number of subjects: 0
Study 12117049 — intervention group
Group type: EXPERIMENTAL
Intervention: TJ-96
Number of subjects: 0
Study 12117049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10428573 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% carbohydrate beverage (C)
Number of subjects: 10
Study 10428573 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (P)
Number of subjects: 10
Study 10428573 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise mode
Number of subjects: 10
Study 7539633 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine, RNA, and omega-3 fatty acids
Number of subjects: 42
Study 7539633 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric and isonitrogenous placebo diet
Number of subjects: 42
Study 2280848 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (MPSS)
Number of subjects: 40
Study 2280848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 507792 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin
Number of subjects: 46
Study 507792 — intervention group
Group type: COMPARATOR
Intervention: Cefoxitin
Number of subjects: 46
Study 28739019 — intervention group
Group type: EXPERIMENTAL
Intervention: Stabilization exercises plus electrotherapy
Number of subjects: 41
Study 28739019 — intervention group
Group type: COMPARATOR
Intervention: Routine exercises plus electrotherapy
Number of subjects: 41
Study 27289482 — intervention group
Group type: EXPERIMENTAL
Intervention: Local fasciocutaneous perforator flap (lFPF)
Number of subjects: 30
Study 27289482 — intervention group
Group type: COMPARATOR
Intervention: Free Gracilis flap (fGF)
Number of subjects: 30
Study 25446057 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 75
Study 25446057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 23522721 — intervention group
Group type: COMPARATOR
Intervention: NSAID therapy (n=24)
Number of subjects: 35
Study 23522721 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (n=11)
Number of subjects: 35
Study 20648213 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic only
Number of subjects: 70
Study 20648213 — intervention group
Group type: COMPARATOR
Intervention: Local anesthetic mixed with non-particulate betamethasone
Number of subjects: 70
Study 18413332 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg extended-release fluvastatin every day
Number of subjects: 27
Study 18413332 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg immediate-release fluvastatin twice a day
Number of subjects: 27
Study 18413332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 15641902 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory modality
Number of subjects: 0
Study 15641902 — intervention group
Group type: COMPARATOR
Intervention: Vision and touch
Number of subjects: 0
Study 12639651 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg
Number of subjects: 3040
Study 12639651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3040
Study 10832825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 300 mg oral once daily for up to 6 months
Number of subjects: 874
Study 10832825 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 874
Study 10832825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 9093182 — intervention group
Group type: EXPERIMENTAL
Intervention: Early follicular endometrial priming with 2 mg 17 beta‐E2 twice per day (group A)
Number of subjects: 14
Study 9093182 — intervention group
Group type: COMPARATOR
Intervention: Midfollicular endometrial priming with 1 to 2 mg/d of 17 beta‐E2 (group B)
Number of subjects: 14
Study 8457235 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 4.8 g
Number of subjects: 5
Study 8457235 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam 9.6 g
Number of subjects: 5
Study 8457235 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam (4.8 g and 9.6 g)
Number of subjects: 5
Study 8457235 — intervention group
Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 5
Study 3954834 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.58 g alcohol/kg body wt as whisky or lager
Number of subjects: 9
Study 3954834 — intervention group
Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 9
Study 31175689 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein dose (exact dosage not specified)
Number of subjects: 0
Study 31175689 — intervention group
Group type: COMPARATOR
Intervention: Low protein dose (exact dosage not specified)
Number of subjects: 0
Study 29790221 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year lifestyle intervention (cholesterol-lowering dietary changes, weight loss, and stopping smoking)
Number of subjects: 1216
Study 29790221 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-year lifestyle intervention
Number of subjects: 1216
Study 29790221 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1216
Study 27246689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) plus cytotoxic chemotherapy
Number of subjects: 0
Study 27246689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) 15 mg/kg dosing
Number of subjects: 0
Study 27246689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) 10 mg/kg dosing
Number of subjects: 0
Study 27246689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) with paclitaxel once per week
Number of subjects: 0
Study 27246689 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (BEV) plus paclitaxel once per week
Number of subjects: 0
Study 27246689 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 24525158 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 173
Study 23158530 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel drug-eluting balloon (DEB)
Number of subjects: 182
Study 23158530 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 182
Study 20579957 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerclage
Number of subjects: 0
Study 20579957 — intervention group
Group type: COMPARATOR
Intervention: Cervical length <25 mm
Number of subjects: 0
Study 18085343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreaticoduodenectomy with extended lymphadenectomy
Number of subjects: 424
Study 18085343 — intervention group
Group type: COMPARATOR
Intervention: Pancreaticoduodenectomy with standard lymphadenectomy
Number of subjects: 424
Study 15814873 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched drink
Number of subjects: 101
Study 15814873 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 12215585 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic atrial fibrillation (AF)
Number of subjects: 25
Study 12215585 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery disease (CAD)
Number of subjects: 25
Study 12215585 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 25
Study 10379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of tubocurarine (TC) 0.15 mg x kg(‐1)
Number of subjects: 0
Study 10379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming dose of vecuronium (VEC) 0.015 mg x kg(‐1)
Number of subjects: 0
Study 10379631 — intervention group
Group type: COMPARATOR
Intervention: Intubation dose of tubocurarine (TC) 0.6 mg x kg(‐1)
Number of subjects: 0
Study 10379631 — intervention group
Group type: EXPERIMENTAL
Intervention: Priming with tubocurarine (TC)
Number of subjects: 0
Study 10379631 — intervention group
Group type: COMPARATOR
Intervention: Priming with vecuronium (VEC)
Number of subjects: 0
Study 8704079 — intervention group
Group type: EXPERIMENTAL
Intervention: Metamizol (1 g/100 ml NaCl 0.9% intravenous over 15 min) plus diclofenac (100 mg suppository)
Number of subjects: 86
Study 8704079 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 86
Study 1473857 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g paracetamol coingested with a meal of white bread
Number of subjects: 15
Study 1473857 — intervention group
Group type: COMPARATOR
Intervention: White bread meal without paracetamol
Number of subjects: 15
Study 6330872 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg ranitidine
Number of subjects: 10
Study 6330872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31633318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic preparation (Crown Prep, Mectron, Carasco, Italy)
Number of subjects: 32
Study 31633318 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique (high-speed contra-angle handpiece, Kavo, Biberach, Germany)
Number of subjects: 32
Study 31633318 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic preparation
Number of subjects: 32
Study 31633318 — intervention group
Group type: COMPARATOR
Intervention: Conventional technique
Number of subjects: 32
Study 29410543 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tochen's formula (birth weight + 5 cm)
Number of subjects: 67
Study 29410543 — intervention group
Group type: COMPARATOR
Intervention: Tochen's formula
Number of subjects: 67
Study 27712311 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific picture book and information sheet
Number of subjects: 104
Study 27712311 — intervention group
Group type: COMPARATOR
Intervention: Routine information and specific picture book
Number of subjects: 104
Study 23909911 — intervention group
Group type: EXPERIMENTAL
Intervention: Development of nephropathy (incidence of urinary albumin excretion rate > 40 mg/24 h)
Number of subjects: 1365